DE602006006855D1 - Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb) - Google Patents
Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb)Info
- Publication number
- DE602006006855D1 DE602006006855D1 DE602006006855T DE602006006855T DE602006006855D1 DE 602006006855 D1 DE602006006855 D1 DE 602006006855D1 DE 602006006855 T DE602006006855 T DE 602006006855T DE 602006006855 T DE602006006855 T DE 602006006855T DE 602006006855 D1 DE602006006855 D1 DE 602006006855D1
- Authority
- DE
- Germany
- Prior art keywords
- phosphorylated
- specific
- map kinase
- alzheimer
- test compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000090 biomarker Substances 0.000 title 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 5
- 108091054455 MAP kinase family Proteins 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000024827 Alzheimer disease Diseases 0.000 abstract 3
- 102000003923 Protein Kinase C Human genes 0.000 abstract 1
- 108090000315 Protein Kinase C Proteins 0.000 abstract 1
- 239000012190 activator Substances 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/90—Enzymes; Proenzymes
- G01N2333/91—Transferases (2.)
- G01N2333/912—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Physiology (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US11/246,524 US7595167B2 (en) | 2005-10-11 | 2005-10-11 | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| PCT/US2005/036014 WO2007043998A1 (en) | 2005-10-11 | 2005-10-11 | Alzheimer’s disease-specific alterations of the erk1/erk2 phosphorylation ratio |
| PCT/US2006/022156 WO2007044094A1 (en) | 2005-10-11 | 2006-06-07 | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
| PCT/US2006/037186 WO2007047029A2 (en) | 2005-10-11 | 2006-09-25 | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DE602006006855D1 true DE602006006855D1 (de) | 2009-06-25 |
Family
ID=37067652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE602006006855T Active DE602006006855D1 (de) | 2005-10-11 | 2006-09-25 | Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb) |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20180024146A1 (enExample) |
| EP (5) | EP2339349B1 (enExample) |
| JP (1) | JP4908514B2 (enExample) |
| KR (2) | KR20140002073A (enExample) |
| AT (1) | ATE431558T1 (enExample) |
| CA (1) | CA2625300C (enExample) |
| DE (1) | DE602006006855D1 (enExample) |
| ES (5) | ES2412268T3 (enExample) |
| TW (2) | TWI448688B (enExample) |
| WO (1) | WO2007044094A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002067764A2 (en) | 2001-02-27 | 2002-09-06 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| US20050065205A1 (en) | 2002-03-07 | 2005-03-24 | Daniel Alkon | Methods for Alzheimer's disease treatment and cognitive enhance |
| US6825229B2 (en) | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| TW201206425A (en) | 2004-05-18 | 2012-02-16 | Brni Neurosciences Inst | Treatment of depressive disorders |
| US7595167B2 (en) | 2005-10-11 | 2009-09-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease-specific alterations of the Erk1/Erk2 phosphorylation ratio |
| US20090029873A1 (en) | 2005-10-11 | 2009-01-29 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's Disease-Specific Alterations of the Erk1/Erk2 Phosphorylation Ratio-Alzheimer's Disease-Specific Molecular Biomarkers (Adsmb) |
| EP2762136A1 (en) * | 2006-07-28 | 2014-08-06 | Blanchette Rockefeller Neurosciences, Institute | Methods of stimulating cellular growth, synaptic remodeling and consolidation of long-term memory |
| EP3332797A3 (en) | 2007-02-09 | 2018-08-01 | Blanchette Rockefeller Neurosciences Institute | Therapeutic effects of bryostatins, bryologs and other related substances on head trauma-induced memory impairment and brain injury |
| JP2011529344A (ja) | 2008-07-28 | 2011-12-08 | ブランシェット・ロックフェラー・ニューロサイエンスィズ・インスティテュート | アルツハイマー病の刺激誘発ゲノムプロフィールマーカー |
| CA2731171C (en) | 2008-07-28 | 2016-10-18 | Blanchette Rockefeller Neurosciences Institute | Pkc-activating compounds for the treatment of neurodegenerative diseases |
| CA2728171A1 (en) * | 2008-08-27 | 2010-03-04 | H. Lundbeck A/S | System and methods for measuring biomarker profiles |
| CN102741693A (zh) * | 2009-10-02 | 2012-10-17 | 布朗歇特洛克菲勒神经科学研究所 | 诊断阿尔茨海默病的成纤维细胞生长模式 |
| CA2776498A1 (en) * | 2009-10-02 | 2011-04-07 | Blanchette Rockefeller Neurosciences Institute | Abnormal alterations of pkc isozymes processing in alzheimer's disease peripheral cells |
| US10317396B2 (en) * | 2011-05-12 | 2019-06-11 | West Virginia University | Peripheral diagnostic methods for screening Alzheimer's disease using beta amyloid and intercellular communication |
| CA2856235A1 (en) | 2011-11-13 | 2013-05-16 | Blanchette Rockefeller Neurosciences Institute | Esters of dcpla for the treatment of neurodegenerative disorders |
| KR101351978B1 (ko) * | 2012-10-30 | 2014-01-16 | 주식회사 코씨드바이오팜 | 참치 안구 파쇄물을 유효성분으로 포함하는 관절염 예방 또는 치료용 약제학적 조성물 및 식품 조성물 |
| CA2935266C (en) * | 2014-01-03 | 2022-02-01 | Blanchette Rockefeller Neurosciences Institute | Convergence of aggregation rate with validated peripheral diagnostics for alzheimer's disease |
| EP3600027A4 (en) | 2017-03-31 | 2020-12-23 | Neurodiagnostics LLC | LYMPHOCYTE-BASED MORPHOMETRIC TEST DEDICATED TO ALZHEIMER'S DISEASE |
| US20220211700A1 (en) * | 2019-05-23 | 2022-07-07 | Indiana University Research And Technology Corporation | Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4374316B2 (ja) * | 1993-01-25 | 2009-12-02 | 武田薬品工業株式会社 | β−アミロイドまたはその誘導体に対する抗体およびその用途 |
| US6107050A (en) | 1993-05-03 | 2000-08-22 | The United States Of America As Represented By The Department Of Health And Human Services | Diagnostic test for alzheimers disease |
| US20030108956A1 (en) * | 1993-05-03 | 2003-06-12 | Alkon Daniel L. | Cell tests for Alzheimer's disease |
| US7427392B1 (en) * | 1994-11-14 | 2008-09-23 | Elan Pharmaceuticals, Inc. | Methods for aiding in the diagnosis of alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau |
| US20030165481A1 (en) * | 2000-02-24 | 2003-09-04 | Hersh Louis B. | Amyloid peptide inactivating enzyme to treat Alzheimer's disease |
| WO2002067764A2 (en) * | 2001-02-27 | 2002-09-06 | Blanchette Rockefeller Neurosciences Institute | Alzheimer's disease diagnosis based on mitogen-activated protein kinase phosphorylation |
| US6825229B2 (en) * | 2002-03-07 | 2004-11-30 | Blanchette Rockefeller Neurosciences Institute | Methods for Alzheimer's Disease treatment and cognitive enhancement |
| KR100574017B1 (ko) | 2003-08-11 | 2006-04-26 | 삼성전자주식회사 | 잉크젯 프린터의 잉크 카트리지 |
| US7199386B2 (en) | 2004-07-29 | 2007-04-03 | General Electric Company | System and method for detecting defects in a light-management film |
-
2006
- 2006-06-07 WO PCT/US2006/022156 patent/WO2007044094A1/en not_active Ceased
- 2006-09-25 ES ES08020258T patent/ES2412268T3/es active Active
- 2006-09-25 ES ES10011288.7T patent/ES2588376T3/es active Active
- 2006-09-25 EP EP10011288.7A patent/EP2339349B1/en active Active
- 2006-09-25 ES ES10012836.2T patent/ES2477284T3/es active Active
- 2006-09-25 EP EP10011289.5A patent/EP2322934B1/en active Active
- 2006-09-25 CA CA2625300A patent/CA2625300C/en active Active
- 2006-09-25 EP EP08020258A patent/EP2031398B1/en active Active
- 2006-09-25 JP JP2008535546A patent/JP4908514B2/ja not_active Expired - Fee Related
- 2006-09-25 EP EP10011290A patent/EP2322936A1/en not_active Withdrawn
- 2006-09-25 AT AT06825096T patent/ATE431558T1/de not_active IP Right Cessation
- 2006-09-25 KR KR1020137031223A patent/KR20140002073A/ko not_active Withdrawn
- 2006-09-25 DE DE602006006855T patent/DE602006006855D1/de active Active
- 2006-09-25 EP EP10012836.2A patent/EP2317321B1/en active Active
- 2006-09-25 ES ES06825096T patent/ES2323813T3/es active Active
- 2006-09-25 ES ES10011289.5T patent/ES2596881T3/es active Active
- 2006-10-11 TW TW095137389A patent/TWI448688B/zh not_active IP Right Cessation
- 2006-10-11 TW TW102146766A patent/TW201413246A/zh unknown
-
2008
- 2008-05-08 KR KR1020087011105A patent/KR101375552B1/ko not_active Expired - Fee Related
-
2017
- 2017-09-29 US US15/719,714 patent/US20180024146A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20140002073A (ko) | 2014-01-07 |
| EP2322936A1 (en) | 2011-05-18 |
| KR101375552B1 (ko) | 2014-03-24 |
| EP2031398A1 (en) | 2009-03-04 |
| ES2412268T3 (es) | 2013-07-10 |
| TW201413246A (zh) | 2014-04-01 |
| ATE431558T1 (de) | 2009-05-15 |
| CA2625300A1 (en) | 2007-04-26 |
| EP2322934B1 (en) | 2016-08-31 |
| EP2339349A1 (en) | 2011-06-29 |
| EP2317321A1 (en) | 2011-05-04 |
| CA2625300C (en) | 2018-01-02 |
| EP2031398B1 (en) | 2013-02-13 |
| JP2009511905A (ja) | 2009-03-19 |
| JP4908514B2 (ja) | 2012-04-04 |
| US20180024146A1 (en) | 2018-01-25 |
| ES2596881T3 (es) | 2017-01-12 |
| TW200801515A (en) | 2008-01-01 |
| EP2339349B1 (en) | 2016-08-17 |
| ES2477284T3 (es) | 2014-07-16 |
| EP2322934A1 (en) | 2011-05-18 |
| ES2323813T3 (es) | 2009-07-24 |
| ES2588376T3 (es) | 2016-11-02 |
| TWI448688B (zh) | 2014-08-11 |
| EP2317321B1 (en) | 2014-04-02 |
| WO2007044094A1 (en) | 2007-04-19 |
| KR20080066785A (ko) | 2008-07-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602006006855D1 (de) | Morbus alzheimer-spezifische veränderungen des erkheimer-spezifische molekulare biomarker (adsmb) | |
| De Bock et al. | Challenges for biomarker discovery in body fluids using SELDI‐TOF‐MS | |
| ATE370414T1 (de) | Verwendung von nicotinamide n-methyltransferase zur diagnose von kolorektalem krebs | |
| ATE491953T1 (de) | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis | |
| WO2003043487A3 (en) | Method of using a non-antibody protein to detect and measure an analyte | |
| ATE540319T1 (de) | Verfahren für die bestimmung von fk506 | |
| ATE493649T1 (de) | Verfahren zur diagnose von polyzystischer nierenkrankheit | |
| WO2005042761A3 (en) | Biomarkers for amyotrophic lateral sclerosis | |
| NO20070949L (no) | Transkriptomdiagnostikk i spytt | |
| ATE514950T1 (de) | Verfahren zur untersuchung von sepsis bei menschen | |
| CA2701341A1 (en) | Method of assessing colorectal cancer from a stool sample by use of the marker combination calprotectin and hemoglobin/haptoglobin complex | |
| DE60021369D1 (de) | Verfahren zur abschätzung eines magengeschwür-risikos | |
| DE60325382D1 (de) | Verfahren zur diagnose von gebärmutterhalskrebs | |
| DE60331857D1 (de) | Markerproteine zur diagnose einer lebererkrankung und verfahren zur diagnose einer lebererkrankung damit | |
| ATE427500T1 (de) | Hamoglobintest fur neonatales screening | |
| ATE545460T1 (de) | Proteomanalyseverfahren für phosphoryliertes protein | |
| WO2007047029A3 (en) | Alzheimer's disease-specific alterations of the erk1/erk2 phosphorylation ratio as alzheimer's disease-specific molecular biomarkers (adsmb) | |
| DE60025170D1 (de) | Diagnostisches verfahren für asthma | |
| DE602004017317D1 (de) | Verwendung der proteine proteinase 3 (prn3) und leukozyten elastatse inhibitor (ileu) als marker für kolorektale karzinome | |
| ATE354095T1 (de) | Verfahren zur detektion von prp unter verwendung ein makrozyklischen ligand | |
| WO2006122053A3 (en) | Biomarkers for evaluating likelihood of tumor sensitivity to an mtor inhibitor | |
| ATE482398T1 (de) | Verfahren zur stratifizierung von herzinsuffizienz | |
| Jin et al. | 2‐D DIGE and MALDI‐TOF‐MS analysis of the serum proteome in human osteosarcoma | |
| ATE504833T1 (de) | Verfahren zur bestimmung des phänotyps von zellen | |
| DE602005013430D1 (de) | Verwendung von asc als marker für kolorektalkarzinome |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8364 | No opposition during term of opposition |